Who We Are

Boston Healthcare consultants bring energy, problem-solving skills and creativity to every client engagement, from strategy development to implementation. We are individuals with outstanding character, sharp analytical minds, and the ability to work effectively with people at all levels in an organization. For these reasons our firm enjoys broad appeal as a place for talented people to grow.

As consultants develop professionally, they become more involved with the leadership of our firm. There are three dimensions of leadership that we consider especially important:

  • Client leadership. Focusing on the whole client organization and its most critical issues; providing counsel to CEOs and other top executives.
  • Thought leadership. Contributing to the firm’s intellectual capital through research and knowledge development.
  • People leadership. Taking responsibility for the performance of project teams; mentoring and having impact on the careers of others.

Joseph V. Ferrara, President and CEO


Joe Ferrara has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and informatics clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovative healthcare technologies. Mr. Ferrara writes and speaks extensively on the subject of the value of medical technology innovation, with a particular focus on pharmacogenomics, specialty pharmaceuticals, and novel therapeutic devices.

Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research.

Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a master’s degree from Harvard University.

Betty Su, Vice President and Managing Director (Asia-Pacific)


Betty Su is Vice President and Managing Director for Boston Healthcare Associates International Hong Kong Limited and leads the firm’s activities in the Asia-Pacific region out of the Shanghai office. She manages a team of consultants supporting clients in Hong Kong, China, and other Asia-Pacific markets, and complementing Boston Healthcare’s global reimbursement and market access advisory services.

Ms. Su specializes in market access and regulatory strategy in China, advising drug, device, and diagnostics companies on commercialization and business development opportunities. She advises biopharmaceutical, medical device, imaging and diagnostics companies in the areas of pricing and reimbursement, sales and marketing, market development, and growth strategy. Prior to her consulting role, Ms. Su held several positions at AstraZeneca in China in marketing, government affairs, and corporate communications.

Ms. Su completed her international MBA degree through a joint program between the Norwegian School of Management and Fudan University in 2007 and has a bachelor’s degree in international marketing from the Shanghai Institute of Foreign Trade.

Linda Wang, Senior Consultant (Asia-Pacific)

Linda Wang, Senior Consultant (Asia Pacific)
Linda Wang is Senior Consultant for Boston Healthcare and focuses on the firm’s activities in the Asia-Pacific region. She has over 14-years of healthcare industry experience in business development and portfolio management. Prior to joining Boston Healthcare, Ms. Wang worked as a project lead for a European healthcare consulting firm. Ms. Wang has previously worked in marketing and strategy development at Kodak HG, Baxter, and Eli Lilly both in APAC and Greater China. She has extensive expertise in leading and managing research-based strategic consulting projects with pharmaceutical, medical consumables/devices, biotech, and life sciences in China and APAC.

Ms. Wang received her MBA from Wayne State University in Michigan and has a BSc degree of Medicine from the Medical School of Beijing University, China.

Jörg Burkowitz, Ph.D., Director


Jörg Burkowitz has 15 years of German reimbursement and market access consulting experience, including an in-depth knowledge of European reimbursement framework requirements. Based in Berlin, he provides advisory services at Boston Healthcare mainly in the topics of market access, reimbursement, and health policy to global pharmaceutical, biotechnological, and medical device manufacturers.

Prior to joining Boston Healthcare, Dr. Burkowitz was a consultant at Alpha Care. He also gained a comprehensive insight into German healthcare policy working as an advisor and head of the MP office of a Member of the Bundestag (Lower House of Federal Parliament). Dr. Burkowitz holds a doctoral degree from the Berlin Medical School Charité, an MPH from Hannover Medical School (MHH), and an MSc from the Free University Berlin.

Thomas F. Goss, PharmD, Senior Vice President


Thomas Goss has more than 20 years of experience managing and directing healthcare research, including examination of the impact of public and private Payor policy on patient access, assessment of health-related quality-of-life, patient preference, and patient satisfaction associated with healthcare interventions, and evaluation of health economic outcomes associated with healthcare innovations. His work in health economic assessment includes the development of health economic evaluations (cost-effectiveness and budget impact analysis) for multiple markets including the U.S., EU-5, Japan, and other markets He also directs disease management program evaluations using patient outcomes data. He has published extensively in these areas and has more than 50 peer-reviewed publications and over 90 peer-reviewed abstracts and invited publications.

Prior to joining Boston Healthcare Associates, Dr. Goss was Vice President and Director of Consulting Services at Covance Market Access Services, where he had a 15-year career with increasing levels of responsibility in the areas of client management and executive management.

Dr. Goss received a Pharm.D. from the State University of New York at Buffalo, and a B.S. from the Albany College of Pharmacy. He completed graduate coursework in Epidemiology and a postdoctoral fellowship in Pharmacoepidemiology and Outcomes Research at the State University of New York at Buffalo. Dr. Goss has authored chapters in the American College of Clinical Pharmacy Textbook Pharmacoeconomics and Outcomes: Applications for Patient Care and has participated in the ACCP Outcomes and Economics Practice Research Network and has held memberships and presented at the International Society of Pharmacoeconomics and Outcomes Research and the Academy of Managed Care Pharmacy. Dr. Goss is currently an appointee to the U.S. Center for Medicare & Medicaid Services (CMS) Medicare Evidence Development & Coverage Advisory Committee (MEDCAC).

Rob Wenthold, Vice President


Rob Wenthold has 15 years of experience providing consulting services to the biopharmaceutical, medical device, and diagnostic companies on commercialization and market access strategy. Mr. Wenthold’s particular focus is global pricing, reimbursement, and market access for innovative medical technologies. He has substantial experience in global markets and managed Boston Healthcare Associates European HQ office in Berlin from 2013-2014. Mr. Wenthold has been responsible for international operations since 2009.

Mr. Wenthold brings an in-depth understanding of global payers and health systems and a rigorous research methodology to properly assess investment opportunities and risks. He has experience supporting several due diligence transactions, embedding pricing and reimbursement risk, and building additional evidence investment and infrastructure development into go/no-go and valuation decisions.

Mr. Wenthold advises start-up and early stage companies as well as large multinationals and has experience across disease types, settings of care and global markets. He is a frequent speaker and moderator at industry conferences in the US and Europe.

Mark Girardi, Vice President


Mark Girardi has over 30 years of experience in life sciences, in vitro diagnostics, and medical devices commercialization and reimbursement. He has had roles in product management, sales and marketing, and most recently in strategy consulting.

Mr. Girardi joins us from GfK Health, a global consultancy and market research firm, where he was Senior Vice President responsible for the MedTech consulting practice. Prior to joining GfK, Mr. Girardi spent five years at Predictive Biosciences as VP of Sales and Marketing. He also served as Senior Director of Marketing at Z-Tech Medical where he was responsible for commercialization of the company’s breast cancer screening devices. As a Director of Marketing at Cytyc Corporation (now Hologic), he managed the worldwide launch of the Thin Prep Imaging System. Mark has also held senior marketing positions at Genzyme Genetics and Millipore.

Mr. Girardi received his BS in Chemistry from Merrimack College and an MS in Analytical Chemistry from the University of New Hampshire.

Binh Ho, Vice President, Finance and Operations

Binh Ho joined Boston Healthcare in 2014 and oversees finance and operations, ranging from staffing to administrative management and strategic financial initiatives that are core to the company’s growth and development. He applies 16 years of financial management experience to the role, providing valuable perspective on how Boston Healthcare can continue to operate as one of the best and most efficient healthcare strategic consulting companies.

With prior roles at Sprint Corporation, Corporate Finance Group, Inc., and Deloitte Consulting, he has managed finance, accounting, corporate training, human resources, information technology, facilities, business development, and client relationships. Mr. Ho holds a BA from Baker University (KS) in Business Management.

.

Timothy Sheflin, Executive Director

Timothy Sheflin has over 10 years of consulting experience assessing the reimbursement environment for medical devices, in vitro diagnostics, pharmaceuticals, specialty drugs and biologics. His work has addressed the private and public payer product evaluation processes, as well as coverage policies and formulary analyses.

Mr. Sheflin has become expert at the design, conduct, and analysis of payer research that produces insightful and actionable strategies. His relationships with medical and pharmacy directors extend across the country within the largest national and regional plans. Mr. Sheflin has also designed tactical reimbursement launch plans and needs assessments for specialty drug companies whose products require physician reimbursement support services and payer accounts management. He has developed and produced over 50 payer research programs, facilitated in-person manufacturer and payer interactions, and participated in manufacturer presentations to commercial evaluation committees. Mr. Sheflin also has extensive experience in developing market access strategies for tests that aid in early cancer detection, personalized drug treatment choices, identification of sexually transmitted diseases, women’s health, and the detection of gastrointestinal disease. In addition, he has developed strategies for novel diagnostic imaging modalities used for detection, treatment planning, and surveillance.

Mr. Sheflin has a BA in Government from Connecticut College.

Shivang Doshi, Director

Shivang Doshi has worked with a variety of pharmaceutical and diagnostics clients on issues related to market access, evidence development and reimbursement strategies of novel diagnostic technologies. His specific areas of expertise include value-based molecular assays, companion diagnostics, and informatics tools that support the delivery of precision medicine.

Mr. Doshi’s prior experiences include cancer drug discovery at Novartis Institutes for Biomedical Research and global health policy at the Dana Farber Cancer Institute.

Mr. Doshi has a Master of Public Health from Harvard School of Public Health and a Master’s degree in Biotechnology from Johns Hopkins University.